• 21 Feb 2022
• Admin
• News Article

Phase III trials of COVID drug Movfor show positive results, says Hetero

Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug, the Hyderabad-based drug maker said in a statement Drug firm Hetero on Saturday announced positive results of Phase III trials of Movfor (Molnupiravir), an investigational oral antiviral COVID-19 medicine. The results, presented as an Oral Abstract at the Conference on Retroviruses and Opportunistic Infections (CROI) held virtually February 12-16, 2022, demonstrated that Molnupiravir along with standard of care (SOC) reduced the risk of hospitalisation by over 65 per cent compared to SOC alone. Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug, the Hyderabad-based drug maker said in a statement. No fatalities were reported during the study Under the Phase III trials, one of the studies included 1,218 COVID-19 patients, it said. The study enrolled eligible patients, within five days of symptom onset, were administered with Molnupiravir capsules(800 mg twice daily) for five days, it added. Hetero entered into a non-exclusive voluntary licensing agreement with MSD in April 2021 for the manufacturing and distribution of Molnupiravir for the treatment of COVID-19. Under this licensing deal, Hetero was allowed to expand access of Molnupiravir in India and in other low-and middle-income countries (LMICs), following the approvals for emergency use authorisation by local regulatory agencies